Stock listing
gettex:0NN Avicanna Inc Aktie
German listing (gettex) of Avicanna Inc · home listing TSX:AVCN
Follow Avicanna Inc into a list and get an email when it puts out news.
Home listing price · TSX:AVCN
$0.085 CAD -0.002 (-2.9%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, TSX:AVCN
- Day range
- $0.080 – $0.085 CADNov 20, 2026
- Volume
- 27,529 sharesNov 20, 2026
- Market cap
- $11.42M CADAt the close on Nov 20, 2026 · price × 134.4M shares outstanding
- 52-week range
- $0.080 – $0.255 CADLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $15,722 CADMedian day 43,700 shares · 7 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| TSX:AVCN · Home | $0.085 CAD | -0.002 (-2.9%) | 27,529 | $0.085 | $0.085 | $0.080 | $0.088 | Close on Nov 20, 2026 |
| OTC:AVCNF | $0.06 USD | -0.003 (-5.4%) | 47,000 | $0.06 | $0.06 | $0.06 | $0.064 | Close on Nov 20, 2026 |
| Frankfurt:0NN | €0.052 EUR | -0.002 (-2.8%) | — | €0.052 | €0.052 | €0.052 | €0.054 | Close on Nov 19, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · TSX:AVCN · CAD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.085 | -0.002 | -2.9% | $0.085 | $0.085 | $0.080 | 27,529 | |
| $0.088 | -0.003 | -2.8% | $0.085 | $0.088 | $0.085 | 28,242 | |
| $0.090 | 0.000 | 0.0% | $0.090 | $0.090 | $0.090 | 119,010 | |
| $0.090 | -0.010 | -10.0% | $0.100 | $0.100 | $0.090 | 201,500 | |
| $0.100 | +0.015 | +17.6% | $0.090 | $0.100 | $0.090 | 110,510 | |
| $0.085 | 0.000 | 0.0% | $0.085 | $0.085 | $0.085 | 39,037 | |
| $0.085 | -0.015 | -15.0% | $0.095 | $0.095 | $0.080 | 4,125,201 | |
| $0.100 | -0.005 | -4.8% | $0.105 | $0.105 | $0.100 | 564,250 | |
| $0.105 | 0.000 | 0.0% | $0.110 | $0.110 | $0.105 | 31,511 | |
| $0.105 | 0.000 | 0.0% | $0.105 | $0.105 | $0.100 | 107,800 | |
| $0.105 | -0.005 | -4.5% | $0.110 | $0.110 | $0.100 | 100,500 | |
| $0.110 | 0.000 | 0.0% | $0.110 | $0.115 | $0.110 | 11,510 | |
| $0.110 | +0.010 | +10.0% | $0.115 | $0.115 | $0.110 | 21,749 | |
| $0.100 | -0.005 | -4.8% | $0.110 | $0.110 | $0.100 | 34,575 | |
| $0.105 | +0.005 | +5.0% | $0.110 | $0.110 | $0.105 | 84,600 | |
| $0.100 | -0.005 | -4.8% | $0.100 | $0.100 | $0.100 | 500 | |
| $0.105 | +0.005 | +5.0% | $0.105 | $0.110 | $0.105 | 52,000 | |
| $0.100 | 0.000 | 0.0% | $0.100 | $0.100 | $0.100 | 501 | |
| $0.100 | 0.000 | 0.0% | $0.100 | $0.100 | $0.100 | 2,500 | |
| $0.100 | 0.000 | 0.0% | $0.100 | $0.100 | $0.100 | 80,514 | |
| $0.100 | 0.000 | 0.0% | $0.100 | $0.100 | $0.100 | 71,600 | |
| $0.100 | 0.000 | 0.0% | $0.100 | $0.100 | $0.100 | 0 | |
| $0.100 | 0.000 | 0.0% | $0.100 | $0.100 | $0.100 | 0 | |
| $0.100 | -0.005 | -4.8% | $0.105 | $0.105 | $0.095 | 337,700 | |
| $0.105 | +0.005 | +5.0% | $0.105 | $0.110 | $0.105 | 63,500 | |
| $0.100 | 0.000 | 0.0% | $0.100 | $0.100 | $0.100 | 0 | |
| $0.100 | -0.015 | -13.0% | $0.105 | $0.105 | $0.100 | 81,500 | |
| $0.115 | 0.000 | 0.0% | $0.115 | $0.115 | $0.115 | 0 | |
| $0.115 | +0.010 | +9.5% | $0.110 | $0.115 | $0.110 | 39,900 | |
| $0.105 | -0.005 | -4.5% | $0.100 | $0.105 | $0.100 | 29,500 | |
| $0.110 | -0.005 | -4.3% | $0.110 | $0.110 | $0.100 | 73,500 | |
| $0.115 | +0.010 | +9.5% | $0.100 | $0.115 | $0.100 | 91,000 | |
| $0.105 | +0.005 | +5.0% | $0.105 | $0.105 | $0.105 | 6,100 | |
| $0.100 | 0.000 | 0.0% | $0.100 | $0.100 | $0.100 | 58,500 | |
| $0.100 | -0.005 | -4.8% | $0.110 | $0.110 | $0.100 | 360,700 | |
| $0.105 | 0.000 | 0.0% | $0.105 | $0.105 | $0.105 | 31,000 | |
| $0.105 | 0.000 | 0.0% | $0.100 | $0.105 | $0.100 | 183,500 | |
| $0.105 | 0.000 | 0.0% | $0.105 | $0.105 | $0.105 | 2,800 | |
| $0.105 | 0.000 | 0.0% | $0.105 | $0.105 | $0.105 | 47,500 | |
| $0.105 | 0.000 | 0.0% | $0.110 | $0.110 | $0.100 | 9,500 | |
| $0.105 | 0.000 | 0.0% | $0.105 | $0.105 | $0.105 | 0 | |
| $0.105 | 0.000 | 0.0% | $0.110 | $0.110 | $0.100 | 52,800 | |
| $0.105 | 0.000 | 0.0% | $0.115 | $0.115 | $0.105 | 16,300 | |
| $0.105 | -0.005 | -4.5% | $0.110 | $0.110 | $0.105 | 91,000 | |
| $0.110 | 0.000 | 0.0% | $0.120 | $0.120 | $0.110 | 21,200 | |
| $0.110 | -0.010 | -8.3% | $0.120 | $0.120 | $0.110 | 56,000 | |
| $0.120 | 0.000 | 0.0% | $0.120 | $0.120 | $0.115 | 12,500 | |
| $0.120 | +0.010 | +9.1% | $0.115 | $0.120 | $0.115 | 17,500 | |
| $0.110 | -0.005 | -4.3% | $0.115 | $0.115 | $0.110 | 83,100 | |
| $0.115 | +0.005 | +4.5% | $0.110 | $0.115 | $0.100 | 1,474,300 | |
| $0.110 | +0.005 | +4.8% | $0.110 | $0.110 | $0.110 | 120,800 | |
| $0.105 | -0.025 | -19.2% | $0.125 | $0.125 | $0.105 | 398,000 | |
| $0.130 | +0.010 | +8.3% | $0.125 | $0.130 | $0.120 | 74,000 | |
| $0.120 | 0.000 | 0.0% | $0.120 | $0.120 | $0.115 | 280,100 | |
| $0.120 | -0.005 | -4.0% | $0.120 | $0.120 | $0.115 | 63,700 | |
| $0.125 | -0.005 | -3.8% | $0.125 | $0.125 | $0.125 | 6,000 | |
| $0.130 | 0.000 | 0.0% | $0.130 | $0.130 | $0.125 | 25,000 | |
| $0.130 | 0.000 | 0.0% | $0.130 | $0.130 | $0.130 | 0 | |
| $0.130 | 0.000 | 0.0% | $0.130 | $0.130 | $0.130 | 1,500 | |
| $0.130 | 0.000 | 0.0% | $0.130 | $0.130 | $0.130 | 0 | |
| $0.130 | -0.010 | -7.1% | $0.130 | $0.130 | $0.130 | 77,100 | |
| $0.140 | +0.010 | +7.7% | $0.135 | $0.140 | $0.135 | 3,500 | |
| $0.130 | -0.005 | -3.7% | $0.130 | $0.130 | $0.130 | 3,600 | |
| $0.135 | +0.005 | +3.8% | $0.140 | $0.140 | $0.130 | 103,600 |
- Ticker
- gettex:0NN
- Asset type
- Stock
- Sector
- Consumer goods
- Industry
- Tobacco & cannabis
- Exchange
- gettex
- Currency
- EUR
What changed lately
Latest news release · Nov 12, 2026
Avicanna Reports Positive Adjusted EBITDA for Q3 2026 and Provides Corporate Update
Latest earnings call · Nov 12, 2026
Avicanna (TSX:AVCN) Q3 2026 Earnings Call
Replay and transcript
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 15 slides
Latest news
Avicanna Reports Positive Adjusted EBITDA for Q3 2026 and Provides Corporate Update
Nov 12, 2026
Closed $0.085 (0.0%) on Nov 12, 2026
Avicanna to Report Q3 2026 Results and Host Call on Nov. 12
Nov 2, 2026
Closed $0.10 (-4.8%) on Nov 2, 2026
Avicanna Announces Closing of Non-Brokered Private Placement of Non-Convertible Debenture Units
Oct 29, 2026
Closed $0.105 (+5.0%) on Oct 30, 2026
Avicanna Transitions US Listing to OTCQB
Oct 16, 2026
Closed $0.10 (-4.8%) on Oct 19, 2026
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
Sep 18, 2026
Closed $0.105 (-4.5%) on Sep 18, 2026
Avicanna to Present at a Life Sciences Investor Forum on September 17, 2026
Sep 15, 2026
Closed $0.12 (0.0%) on Sep 15, 2026
Avicanna Launches MyMedi.ca Integrated Healthcare Program in Canada
Sep 9, 2026
Closed $0.11 (+4.8%) on Sep 9, 2026
Avicanna Announces Closing of Strategic Non-Brokered Private Placement
Aug 19, 2026
Closed $0.13 (+4.0%) on Aug 19, 2026
Avicanna Reports Q2 2026 Financial Results
Aug 14, 2026
Closed $0.13 (-3.7%) on Aug 17, 2026
Avicanna Introduces QUIX™ Rapid-Onset Medical Cannabis Portfolio
Jul 16, 2026
Closed $0.13 (+8.3%) on Jul 16, 2026
Avicanna Inc on 6ix
- Sector
- Consumer goods
- Industry
- Tobacco & cannabis
- News releases
- 24 in the last 12 months · 107 in all · newest Nov 12, 2026 · oldest 2019
- Calls
- 4 calls with a replay · 4 with a transcript · latest Nov 12, 2026
- Decks
- 19 decks · latest November 2026
Where Avicanna Inc is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| TSX:AVCN · Home listing | TSX | Canada | CAD |
| OTC:AVCNF | OTC | United States | USD |
| Cboe Canada:AVCN | Cboe Canada | Canada | CAD |
| LS Exchange:A2PN04 | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2PN04 | Lang & Schwarz | Germany | EUR |
| gettex:0NN · This page | gettex | Germany | EUR |
| Frankfurt:0NN | Frankfurt | Germany | EUR |
| Munich:0NN | Munich | Germany | EUR |
| Stuttgart:0NN | Stuttgart | Germany | EUR |
Valuation
EV/sales 0.5× against a median of 1.1×: 4th lowest of 9 Tobacco & cannabis companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $11.53M CAD
- P/E
- Loss
- EV/sales
- 0.5×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.2×
- Gross margin
- 53.1%
- Operating margin
- −9.2%
- Net margin
- −10.9%
- Debt to equity
- 0.1×
- Beta vs S&P/TSX Composite
- 0.22
Tobacco & cannabis: the 10 companies nearest in size, of 97 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Avicanna Inc · TSX:AVCN | US$7.97M | US$8.04M | n/a | 0.5× | n/a | 2.2× | −10.9% | 0.1× | 0.22 |
| Kombinat Konopny SA · NEWCONNECT:KMB | US$11.75M | US$12.82M | n/a | n/a | n/a | 8.6× | n/a | 0.9× | n/a |
| 1CM Inc. · CSE:EPIC | US$10.67M | US$3.97M | 3.2× | 0.1× | 1.9× | 0.5× | 6.3% | 0.0× | -0.44 |
| PT Indonesian Tobacco Tbk · IDX:ITIC | US$8.60M | US$16.31M | n/a | n/a | n/a | 0.4× | n/a | 0.3× | n/a |
| Kumulus Vape SA · EURONEXT:ALVAP | US$8.31M | US$4.04M | 7.6× | 0.1× | 1.4× | 0.4× | 1.7% | 0.2× | n/a |
| Red White & Bloom Brands, Inc. · CSE:RWB | US$8.20M | US$259.4M | n/a | 7.3× | 2,797× | n/a | −121.5% | n/a | -0.29 |
| HYTN Innovations Inc · CSE:HYTN | US$8.02M | US$7.97M | n/a | 3.0× | n/a | n/a | −46.9% | n/a | 0.05 |
| VPR Brands, LP · OTC:VPRB | US$7.80M | −US$12.33M | 0.4× | −4.6× | n/a | n/a | 737.8% | n/a | -0.73 |
| Greenway Greenhouse Cannabis Corp. · CSE:GWAY | US$7.45M | US$8.65M | n/a | 1.5× | n/a | 1.5× | −37.9% | 0.4× | -0.13 |
| PharmaCielo Ltd. · TSXV:PCLO | US$5.39M | US$5.34M | n/a | 2.1× | n/a | n/a | −103.1% | n/a | -0.16 |
| Ecs Botanics Holdings Ltd · ASX:ECS | US$5.32M | US$8.44M | n/a | 0.6× | n/a | 0.3× | −9.1% | 0.3× | n/a |
| Median of the others | US$8.11M | US$8.20M | 3.2× | 1.1× | 1.9× | 0.5× | −23.5% | 0.3× | -0.22 |
Team and board
Officers
| Officer | Role |
|---|---|
| Aras Azadian | Chief Executive Officer |
Board
| Director | Role |
|---|---|
| Chandra Panchal | Chair |
| Assad J. Kazeminy | Director |
| Flavio Jose Zaclis | Director |
| Giancarlo Davila Char | Director |
| Lisa McCormack | Director |
| Michael Kott | Director |
| Ozgur Kilic | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Avicanna (TSX:AVCN) Q3 2026 Earnings Call | Thu, Nov 12, 2026 · 8:30 AM ET | Replay |
| Avicanna (TSX:AVCN) Q4 2025 Earnings Call | Tue, Apr 07, 2026 · 8:00 AM ET | Replay |
| Avicanna (TSX:AVCN) Q4 2023 Earnings Call | Tue, Apr 02, 2024 · 8:30 AM ET | Replay |
| Avicanna (TSX:AVCN) Q3 2023 Earnings Call | Wed, Nov 15, 2023 · 9:30 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · Before open | 0.0% |
| Q2 2026 | Aug 13, 2026 · After close | +3.9% |
| Q1 2026 | May 13, 2026 · Before open | −3.9% |
| Q3 2025 | Nov 13, 2025 · After close | −5.6% |
| Q2 2025 | Aug 14, 2025 · After close | 0.0% |
| Q1 2025 | May 14, 2025 · After close | +18.8% |
| Q3 2024 | Nov 14, 2024 · After close | −7.8% |
| Q2 2024 | Aug 14, 2024 · After close | +4.5% |
| Q1 2024 | May 13, 2024 · After close | +15.2% |
| Q3 2023 | Nov 14, 2023 · After close | −5.9% |
All 19 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2023 | Aug 14, 2023 · After close | 0.0% |
| Q1 2023 | May 15, 2023 · After close | −6.8% |
| Q4 2022 | Mar 30, 2023 · After close | 0.0% |
| Q3 2022 | Nov 11, 2022 · After close | −1.6% |
| Q2 2022 | Aug 15, 2022 · After close | +8.3% |
| Q1 2022 | May 11, 2022 · After close | 0.0% |
| Q4 2021 | Mar 30, 2022 · After close | −9.7% |
| Quarter to Sep 30, 2021 | Nov 12, 2021 · Before open | +2.7% |
| Quarter to Jun 30, 2021 | Sep 3, 2021 · After close | 0.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 15 slides | November 2026 |
| Investor Presentation (November 2026) | Investor deck | 14 slides | November 2026 |
| Investor Presentation (November 2026) | Investor deck | 14 slides | November 2026 |
| Investor Presentation (September 2026) | Investor deck | 16 slides | September 2026 |
| Investor Presentation (June 2025) | Investor deck | 26 slides | June 2025 |
| Investor Presentation (April 2024) | Investor deck | 24 slides | Apr 25, 2024 |
| Investor Presentation (April 2024) | Investor deck | 24 slides | Apr 1, 2024 |
| Investor Presentation (September 2023) | Investor deck | 26 slides | Sep 6, 2023 |
| Investor Presentation (July 2023) | Investor deck | 24 slides | July 2023 |
| Investor Presentation (March 2023) | Investor deck | 24 slides | Mar 14, 2023 |
All 19 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2022) | Investor deck | 10 slides | September 2022 |
| Investor Presentation (August 2022) | Investor deck | 28 slides | Aug 5, 2022 |
| Investor Presentation (August 2022) | Investor deck | 7 slides | Aug 5, 2022 |
| Investor Presentation (August 2022) | Investor deck | 7 slides | Aug 5, 2022 |
| Investor Presentation (August 2022) | Investor deck | 6 slides | Aug 5, 2022 |
| Investor Presentation (August 2022) | Investor deck | 7 slides | Aug 5, 2022 |
| Investor Presentation (July 2022) | Investor deck | 34 slides | July 2022 |
| Investor Presentation (May 2020) | Investor deck | 25 slides | May 11, 2020 |
| Investor Presentation (March 2019) | Investor deck | 18 slides | March 2019 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of non-convertible debenture units Closed: C$2M raised · C$1,000 a unit · Warrants at C$0.2 for 36 months · free to trade Mar 1, 2027 Use of proceeds: General working capital, G&A expenses, production and manufacturing expenditures, and research and clinical development | Oct 29, 2026 | US$1.43M |
| Private placement of units Closed: C$500,000 raised · C$0.15 a unit · ½ warrant at C$0.2 Buyers: Michael Porter Use of proceeds: General working capital, G&A expenses, production and manufacturing expenditures, and research and clinical development | Aug 19, 2026 | US$361,690 |
| Private placement of units Closed: C$1.55M raised · C$0.2 a unit · ½ warrant at C$0.25 Use of proceeds: General working capital, G&A expenses, production and manufacturing expenditures, and research and clinical development | Feb 10, 2026 | US$1.14M |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in CAD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.5M | 25.5M | 16.8M | 4.05M | 3.27M | 1.57M | 168.3K | 118.0K | 26.7K | 0 |
| Cost of revenue | 12.6M | 12.6M | 10.1M | 2.93M | 437.1K | 2.14M | 76.1K | 172.7K | ||
| Gross profit | 12.8M | 12.9M | 6.66M | 1.11M | 2.83M | -570.0K | 92.1K | -54.7K | 26.7K | |
| Research and development | 256.4K | 178.2K | 330.7K | 276.9K | 304.3K | 376.3K | 1.22M | 456.6K | 23.7K | 0 |
| Selling, general and administrative | 11.7M | 12.9M | 11.9M | 9.61M | 12.5M | 15.8M | 20.5M | 7.69M | 2.48M | 27.1K |
| Operating income | -2.72M | -4.68M | -7.93M | -10.4M | -11.4M | -19.0M | -23.2M | -8.45M | -2.59M | -29.8K |
| Depreciation and amortization | 743.1K | 853.7K | 777.3K | 887.3K | 894.0K | 1.09M | 923.5K | 172.7K | 63.2K | 358.0K |
| EBITDA | -1.97M | -3.83M | -7.16M | -9.52M | -10.5M | -17.9M | -22.3M | -8.27M | -2.52M | 328.2K |
| Interest expense | 51.8K | 333.6K | 610.3K | 1.67M | 738.1K | 263.1K | 54.8K | 0 | 0 | 0 |
| Income before tax | -2.76M | -3.62M | -8.74M | -14.7M | -16.8M | -35.0M | -23.2M | -7.29M | -2.60M | -29.8K |
| Income tax | -857.5K | 2.48M | 13.8K | -2.19M | -1.03M | 1.03M | 1.76K | -358.0K | ||
| Net income | -2.84M | -3.62M | -8.74M | -14.7M | -16.8M | -32.9M | -22.2M | -7.10M | -2.60M | -29.8K |
| Earnings per share, basic | -0.02 | -0.04 | -0.10 | -0.25 | -0.41 | -1.12 | -1.08 | -0.45 | -0.19 | -0.00 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 280.6K | 448.0K | 477.2K | 1.19M | 31.0K | 1.27M | 441.8K | 69.3K | 1.18M | 91.4K |
| Short-term investments | 0 | 1.25M | 0 | 0 | 10.0K | 0 | ||||
| Receivables | 3.55M | 2.75M | 2.97M | 2.15M | 2.34M | 1.01M | 1.20M | 258.6K | 75.3K | 1.48K |
| Inventory | 3.85M | 3.97M | 4.54M | 3.24M | 4.09M | 1.93M | 1.60M | 147.0K | 1 | -1.48K |
| Current assets | 7.90M | 7.64M | 8.46M | 7.06M | 7.35M | 6.77M | 3.95M | 1.19M | 1.31M | 92.9K |
| Property, plant and equipment | 11.3M | 12.0M | 10.4M | 14.5M | 21.8M | 23.2M | 16.3M | 460.9K | 0 | |
| Goodwill | 334.0K | 334.0K | 334.0K | 0 | 0 | 3.21M | 3.21M | |||
| Total assets | 21.2M | 20.1M | 22.0M | 17.6M | 22.3M | 30.2M | 45.2M | 28.2M | 2.12M | 93.0K |
| Accounts payable | 8.51M | 7.77M | 8.87M | 4.75M | 7.29M | 6.56M | 5.18M | 1.46M | 547.9K | 12.8K |
| Current liabilities | 9.18M | 9.27M | 12.0M | 11.4M | 12.2M | 12.8M | 8.72M | 1.79M | 1.28M | 122.8K |
| Long-term debt | 179.6K | 415.8K | 0 | 715.6K | 14.4K | 0 | ||||
| Total debt | 109.2K | 1.80M | 3.21M | 1.66M | 1.94M | 1.27M | 14.4K | 110.0K | ||
| Total liabilities | 9.86M | 10.4M | 14.0M | 14.2M | 15.4M | 16.2M | 15.3M | 1.80M | 1.28M | 122.8K |
| Shareholders' equity | 2.84M | 2.31M | -112.5K | -383.6K | 1.15M | 6.02M | 22.4M | 18.3M | 841.1K | -29.8K |
| Shares outstanding | 114.7M | 100.0M | 84.7M | 59.2M | 41.3M | 29.4M | 20.5M | 15.6M | 13.6M | 19.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -1.18M | -2.55M | -1.40M | -7.44M | -11.7M | -14.0M | -19.4M | -4.99M | -2.13M | -18.6K |
| Capital spending | -255.9K | -402.6K | -557.6K | -66.8K | -789.2K | -1.46M | -7.49M | -3.92M | -512.4K | -512.4K |
| Free cash flow | -1.44M | -2.95M | -1.96M | -7.50M | -12.5M | -15.4M | -26.9M | -8.91M | -2.65M | -18.6K |
| Cash from investing | -255.8K | -402.6K | -3.05M | 810.2K | 760.8K | -2.71M | -7.49M | -7.04M | -663.7K | -663.7K |
| Cash from financing | 963.2K | 3.41M | 3.55M | 9.90M | 10.1M | 17.4M | 27.3M | 10.9M | 3.88M | 110.0K |
| Share buybacks | 4.93M | 3.34M | 9.08M | 9.18M | 12.9M | 20.9M | 10.5M | 4.07M | 0 | |
| Change in cash | -167.4K | -29.2K | -716.8K | 1.16M | -1.24M | 825.0K | 372.5K | -1.11M | 1.09M | 91.4K |
Cap table
Built by 6ix from Avicanna Inc’s releases · as of Oct 29, 2026
- Common shares
- 134,383,851
- Fully diluted
- 139,925,518
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 134,383,851 | Aug 19, 2026 |
| Warrants | 5,541,667 | Aug 19, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · C$0.20 · expire about Oct 2029 |
| Warrants · C$0.20 · expiry not stated |
| Warrants · C$0.25 · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Aug 19, 2026 | 134,383,851 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Aras Azadian | Chief Executive Officer · Since at least Nov 2, 2026 |
| Assad J. Kazeminy | Director · Since at least Nov 5, 2026 |
| Chandra Panchal | Chair · Since at least Nov 5, 2026 |
| Flavio Jose Zaclis | Director · Since at least Nov 5, 2026 |
| Giancarlo Davila Char | Director · Since at least Nov 5, 2026 |
| Greg Young | VP Corporate Services · Sep 18, 2026 – Nov 5, 2026 · Past |
| John M. Viglotti | SVP Corporate Services · Mar 13, 2026 – Nov 5, 2026 · Past |
| Lisa McCormack | Director · Since at least Aug 14, 2026 |
| Michael Kott | Director · Since at least Dec 23, 2025 |
| Ozgur Kilic | Director · Since at least Aug 14, 2026 |
Log in to ask 6ix AI your own questions about Avicanna Inc.